Here, Dave Maheu, VP, Head of Process & Analytical Development at Candel Therapeutics and Curran Simpson, Chief Operating Officer at REGENXBIO detail the key factors driving the adeno associated virus manufacturing market.
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Please enter your email address and create a password to access the full content, Or
log in to your account to continue.
Please tell us more about you so that we can customize our newsletters to your specific interests: